Arthritis plagues Americans, resulting in pain, decreased mobility and even inability to function. Although many treatments are available, most do not address the root cause of the problem or may even make issues worse.
A2M (Alpha-2-Macroglobulin) is an injection targeting arthritic disease progression by promoting joint health. A2M interferes with the enzymes that lead to cartilage breakdown, thus potentially slowing or halting the progression of osteoarthritis. Protecting the joint at the biochemical level may lead to long-term preservation of joint function.
In contrast, Hyaluronic Acid (HA) injections provide only temporary relief by lubricating and cushioning the joint. HA can last anywhere from a few weeks to several months - but does not impact the ongoing progression of the disease.
A2M includes anti-inflammatory properties. Reduced inflammation not only decreases pain, it helps protect the cartilage from further damage. While HA provides some indirect anti-inflammation effects through improved joint function and reduced friction - its impact is minimal compared to A2M.
A2M has the potential to offer long-term benefits due to targeting enzymes responsible for cartilage breakdown. This could mean fewer treatments over time and a slower progression of osteoarthritis. HA often requires repeated injections every 6-12 months to maintain effects as it manages symptoms rather than long-term joint preservation.
A2M also works to repair injured joints due to exercise, accidents and overuse. Its mechanism of action is the same as with arthritic issues.
.png)
.png)